Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.

Molecular cancer therapeutics - 1 Feb 2015

Egile Coumaran, Kenigsberg Mireille, Delaisi Christine, Bégassat Françoise, Do-Vale Véronique, Mestadier Jessica, Bonche Fabrice, Bénard Tsiala, Nicolas Jean-Paul, Valence Sandrine, Lefranc Céline, Francesconi Elisa, Castell Christelle, Lefebvre Anne-Marie, Nemecek Conception, Calvet Loreley, Goulaouic Hélène

Abstract excerpt

Activation of the MET/HGF pathway is common in human cancer and is thought to promote tumor initiation, metastasis, angiogenesis, and resistance to diverse therapies. We report here the pharmacologic characterization of the triazolopyridazine derivative SAR125844, a potent and highly selective inhibitor of the MET receptor tyrosine kinase (RTK), for intravenous administration. SAR125844 displayed nanomolar...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Administration, Intravenous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azoles

Share to Benzothiazoles

Share to Gene Amplification

Share to Mice, SCID

Share to Proto-Oncogene Proteins c-met

Source

Identifiers

PMID: 25504634
DOI: 10.1158/1535-7163.MCT-14-0428

Genes

MET
HGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.PMID 25504634Read ↗

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.Semantic proximity Read ↗

Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical CandidatesSemantic proximity Read ↗

Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of Imatinib-Resistant GIST.Semantic proximity Read ↗

NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants.Semantic proximity Read ↗

MET receptor tyrosine kinase as a therapeutic anticancer target.Semantic proximity Read ↗

In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer ModelsSemantic proximity Read ↗

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity <i>in vivo</i>Semantic proximity Read ↗

Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.Semantic proximity Read ↗

Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.Semantic proximity Read ↗

Forty‐nine gastric cancer cell lines with integrative genomic profiling for development of c‐MET inhibitorSemantic proximity Read ↗

Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells.Semantic proximity Read ↗

<i>MET</i> and <i>KRAS</i> Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.